AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03004287
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by vein: days 1-4 (continuous infusion) of Induction
Trial: NCT03556696
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil Ce target can range from 0 to 10 ng.ml-1. Remifentanil target is adapted in order to maintain Analgesia Nociception Index (MDMS, Loos, France) in the \[50-70\] range.
Trial: NCT03163238
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One syringe contain normal saline in 5 ml in Saline group. Second syringe (50 ml) will contain normal saline (0.9%) alone in rate of infusion (1 ml/kg) in Saline group
Trial: NCT02704429
Drug: PRN1008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A dosing was initiated administering 400 mg BID. Intrapatient dose adjustments (reductions and increases) were permitted based upon tolerability and clinical response with the maximum dose allowed up to 600 mg BID for 12 weeks.~Part B initial dosing was 400 mg QD for 2 weeks with dose escalation to 400 mg BID at the discretion of the Investigator for the purposes of investigating dose response and identifying the minimal efficacious dose of rilzabrutinib for 24 weeks.
Trial: NCT00104104
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg zoledronic acid in 250 mL of calcium-free solution (i.e., 0.9% sodium chloride or 5% glucose) administered intravenously.
Trial: NCT00630032
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m² every 3 weeks
Trial: NCT00630032
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m² every 3 weeks
Trial: NCT00870493
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: starch tablet, 300 mg/day
Trial: NCT04713319
Drug: Panavital
RxNorm normalized name: NIACINAMIDE 2 g in 100 g / ADENOSINE 0.04 g in 100 g TOPICAL CREAM [TAEYANGSOO Plavital RxCream]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the morning and evening a dose of Placebo or D-glyceric acid (DGA) calcium salt dehydrate (Panavital) dissolved into 1.8 dl of water.
Trial: NCT06456723
Drug: [18F]-FET-βAG-TOCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single I.V. administration of a \[18F\]fluoroethyl triazole \[Tyr3\]Octreotate (\[18F\]-FET-βAG-TOCA) - maximum injected dose of 370MBq - followed PET/CT imaging.
Trial: NCT02798523
Drug: Topical methylprednisolone (Advantan emulsion 0 /1%)
RxNorm normalized name: methylprednisolone Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g Advantan emulsion 0.1% (Bayer) contains methylprednisolone aceponate (21-acetoxy-11beta-hydroxy-6alpha-methyl-17-propionyloxy-1,4-pregnadiene-3,20-dione) 1 mg, as the active ingredient. It is an oil-in-water emulsion containing medium chain triglycerides, caprylic-capric-stearic triglyceride, polyoxyethylene alcohol 2-stearyl ether, polyoxyethylene alcohol-21-stearyl ether, benzyl alcohol, disodium edetate, glycerol, and purified water.
Trial: NCT02489630
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1ml/kg normal saline placebo
Trial: NCT02489630
Drug: opiate analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1mg/kg dose of morphine (or morphine equivalent) at 30 min time intervals based on patient pain score or more frequently upon request
Trial: NCT00025649
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00025649
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02234011
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01125891
Drug: ON 01910.Na
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose of ON 01910.Na is 600 mg/m2 as a 2 hour intravenous (i.v.) infusion on days 1, 4, 8, 11, 15 and 18 of a 28-day course. The dose of ON 01910.Na will be escalated in increments in successive cohorts (dose level (DL) 1 = 600 mg/m2, DL 2 = 1200 mg/m2, DL 3 = 1800 mg/m2) of new patients.
Trial: NCT01821677
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00538733
Drug: clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During T-BiRD Phase • Clarithromycin (500mg twice daily for each 28 day cycle)~During BiRD Phase:~• Clarithromycin (500mg twice daily for each 28 day cycle)
Trial: NCT04036617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD cohorts will receive 1 dose of placebo between 10-150 mg. MAD cohorts will receive 7 days dosing of placebo between 70-150mg
Trial: NCT00813475
Drug: Basal bolus insulin regimen (tight glucose control)
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal bolus insulin regimen
Trial: NCT00813475
Drug: Basal bolus insulin regimen (standard control)
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: basal bolus insulin regimen
Trial: NCT03682796
Drug: TRPH-222
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered by IV, 21-day Cycle
Trial: NCT03118843
Drug: SOF/VEL/VOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100/100 mg FDC tablet administered orally once daily with food
Trial: NCT04283877
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 10 mg oral lactose tablet for all participants
Trial: NCT03044665
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will start rosuvastatin 20 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level as current US guideline.
Trial: NCT03044665
Drug: Rosuvastatin plus ezetimibe
RxNorm normalized name: ezetimibe / rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will start single combination pill of rosuvastatin 10 mg plus ezetimibe 10 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level.
Trial: NCT01982201
Drug: Tums 500 mg and 750 mg
RxNorm normalized name: calcium carbonate 500 MG [Tums]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01719575
Drug: Motilitone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01719575
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01790438
Drug: LY2605541
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01056107
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous injection daily
Trial: NCT01790438
Drug: Human Insulin NPH
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01790438
Drug: Oral Antihyperglycemic Medications (OAM)
RxNorm normalized name: ANTIHYPOGLYCEMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03270787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo Placebo,10pills,tid,treat 1 weeks.
Trial: NCT01419990
Drug: GLPG0634
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG0634 300 mg oral capsules, qd, 10 days
Trial: NCT01419990
Drug: GLPG0634
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG0634 450 mg oral capsules, qd, 10 days
Trial: NCT01419990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsules, qd, 10 days
Trial: NCT02981472
Drug: Vitamin K Antagonist (VKA)
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT02981472
Drug: Low Molecular Weight Heparin (LMWH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT00565500
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: celecoxib capsules 200 mg bid for 1 week
Trial: NCT00565500
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen tablets 600 mg tid for 1 week
Trial: NCT03814447
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose: 300mg/m2/d
Trial: NCT00565500
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules tid for 1 week
Trial: NCT02669563
Drug: [18F]4F-MHPG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection of \[18F\]4F-MHPG
Trial: NCT02669563
Drug: [18F]3F-PHPG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection of \[18F\]3F-PHPG
Trial: NCT03340740
Drug: Placebo - Concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar-appearing liquid to cetirizine oral suspension
Trial: NCT00502060
Drug: AZD2171
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00502060
Drug: ZD1839
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02158533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
Trial: NCT00920543
Drug: FSC 100/50mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily dosing
Trial: NCT00920543
Drug: FSC 500/50mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily dosing
Trial: NCT04419506
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching BI 1015550 taken orally as film-coated tablets (matching the respective BI 1015550 tablets) twice daily, in the morning and in the evening for 12 weeks.
Trial: NCT00395044
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02842567
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will treated with 2 identical placebo pills daily given orally for 16 weeks.
Trial: NCT01748994
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02396862
Drug: Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant and Human Factor VIII / Used on demand or prophylaxis of bleeds
Trial: NCT01606488
Drug: Florbetapir F 18 (18F-AV-45)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV bolus injection of 370 MBq (10mCi) florbetapir will be administered approximately 50 minutes prior to a 10 minute PET scan.
Trial: NCT03780517
Drug: BOS172738
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT04372589
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) Preferred therapeutic anticoagulant is enoxaparin. Generally regimens: 1.5 mg/kg subcutaneous once daily or 1 mg/kg subcutaneous twice daily. Alternatively, other subcutaneous LMWH used, including tinzaparin (175 anti-Xa IU/kg subcutaneous once daily) or dalteparin (200 IU/kg subcutaneous once daily or 100 IU/kg subcutaneous twice a day).~Unfractionated heparin (UFH) Commenced, administered, and monitored according to local hospital policy, and guidelines that are used for the treatment of venous thromboembolism (i.e. not for acute coronary syndrome). Intravenous infusion of UFH is according to total body weight and pragmatically adjusted according to local institutional policy to achieve an activated partial thromboplastin time (aPTT) of 1.5-2.5x the reference value. If UFH is used, the availability of a local hospital policy that has specifies an aPTT target in this range or an anti-Xa value is a requirement.
Trial: NCT03661385
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Addition of nitric oxide 20ppm into bypass circuit
Trial: NCT01037712
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00465569
Drug: cow's milk powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk powder given orally in escalating doses to a goal of 500 mg for approximately 23 weeks
Trial: NCT01015443
Drug: Single low dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single intravenous (IV) infusion of 300 milligram per square meter (mg/m\^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first administration of tecemotide.
Trial: NCT01015443
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 8 consecutive weekly subcutaneous vaccinations of tecemotide (L-BLP25) matching placebo at Week 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance treatment at 6-Week intervals, beginning at Week 14, until PD is documented or the subject discontinues for any other reason.
Trial: NCT04334148
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral self administered tablet
Trial: NCT03501212
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Cream 2.5gr applied to both wrist
Trial: NCT00796783
Drug: Cushing's syndrome confirmation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01508676
Drug: Placebo (2.3% DMSO solution)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02614794
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle
Trial: NCT02614794
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose twice daily
Trial: NCT04498910
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT03426969
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01189773
Drug: ibuprofen and codeine
RxNorm normalized name: codeine and ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen: 10 mg/kg (max = 600 mg), codeine: 1 mg/kg (max = 60 mg)
Trial: NCT01181960
Drug: Other Antipsychotics - New Starts
RxNorm normalized name: ANTIPSYCHOTICS,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the other antipsychotic cohort may be newly started on any oral or injectable antipsychotic other than Risperidone long acting injectable and Paliperidone Palmitate
Trial: NCT00921921
Drug: HFA-BDP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFA-BDP 100 mcg bid for 3 weeks, then 400 mcg bid for 3 weeks
Trial: NCT00921921
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 puff bid for 3 weeks, then 1 puff bid for 3 weeks
Trial: NCT02573844
Drug: Proklama
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02573844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01272531
Drug: Mood stabilizer treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lithium or valproate
Trial: NCT00069121
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 milligrams per square metre of body surface area (mg/m\^2) orally twice daily on days 1-15 of each 3-week cycle.
Trial: NCT00069121
Drug: Leucovorin (LV)
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered by one of two regimens, as specified in the arm description.
Trial: NCT02354001
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule daily for 12 week trial - lactose
Trial: NCT01115712
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (to match pioglitazone 30 mg) once daily
Trial: NCT01115712
Drug: Comparator: Hyperinsulinemic Euglycemic Clamp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of Glucose (20% dextrose) to achieve a glucose concentration of 90mg/dL; Infusion of Insulin at a rate of 10 mU/m2/minute from 0 to 180 minutes and at a rate of 40 mU/m2/minute from 180 to 360 minutes; Saline infusion at 60 minutes before the insulin and glucose infusions to keep the antecubital vein open.
Trial: NCT02243566
Drug: MicardisPlus®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02319772
Drug: BCX4430
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02319772
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01457339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Capsule(s) for oral use taken once daily for 30 days
Trial: NCT01925521
Drug: Part1 : OPS-2071
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose under fasted condition
Trial: NCT01925521
Drug: Part1 : Placebo of OPS-2071
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose under fasted condition
Trial: NCT01925521
Drug: Part2 : OPS-2071
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple twice-daily oral dosing for 5-7days
Trial: NCT01925521
Drug: Part2 : Placebo of OPS-2071
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple twice-daily oral dosing for 5-7days
Trial: NCT00097266
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets/capsules, oral, 0 mg, once daily, 3 weeks (switched to arm B for an additional 9 weeks).
Trial: NCT01242527
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules (1g) daily for 12 weeks
Trial: NCT01096667
Drug: Placebo to ertuglilflozin 25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to ertuglilflozin tablet 25 mg once daily for 28 days
Trial: NCT01944215
Drug: Caffeine Tablet
RxNorm normalized name: Caffeine Tablets
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: effect of caffeine
Trial: NCT01242527
Drug: omefas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules (1g) + 2 placebo daily for 12 weeks
Trial: NCT01242527
Drug: omefas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules (1g) + 1 placebo daily for 12 weeks
Trial: NCT01242527
Drug: omefas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules (1g)daily for 12 weeks
Trial: NCT02232789
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oal dose placebo
Trial: NCT00003937
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003937
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01919411
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this arm will receive 7 days of placebo after surgery.
Trial: NCT00524303
Drug: FEC75
RxNorm normalized name: Fluorouracil, Epirubicin, Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5FU 500mg/m2 + Epirubicin 75 mg/m2 + cyclophosphamide 500 mg/m2 IV on day 1 of 4 (21 day) cycles
Trial: NCT03478683
Drug: FF/UMEC/VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning
Trial: NCT03478683
Drug: Placebo to match FF/UMEC/VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
Trial: NCT01690832
Drug: standard saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure
Trial: NCT02986451
Drug: clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle.
Trial: NCT04135781
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capetabine（1000 mg/m2 po, d1-14 bid ）
Trial: NCT04538950
Drug: radioactive drug (tracer)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A radioactive drug (tracer) is used in the PET scan.
Trial: NCT00853905
Drug: balanced salt solution BSS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At end of standard glaucoma surgery, the anterior chamber is reformed with balanced salt solution or viscoelastic to an adequate intraocular pressure.
Trial: NCT00989703
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution, daily for 14 days
Trial: NCT00989703
Drug: GLPG0259
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution
Trial: NCT00989703
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7.5 mg (3 tablets, 2.5 mg/tablet) on study days D-1 and D14
Trial: NCT02203682
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet placebo for 12 weeks
Trial: NCT02764619
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no